Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Nabriva Therapeutics AG (NBRV : NSDQ)
 
 • Company Description   
Nabriva Therapeutics is a biopharmaceutical company engaged in the research and development of new medicines to treat serious bacterial infections, with a focus on the pleuromutilin class of antibiotics. Nabriva Therapeutics' medicinal chemistry expertise has enabled targeted discovery of novel pleuromutilins, including both intravenous and oral formulations. Nabriva Therapeutics' lead product candidate, lefamulin, is a novel semi-synthetic pleuromutilin antibiotic with the potential to be the first-in-class available for systemic administration in humans. The company believes that lefamulin is the first antibiotic with a novel mechanism of action to have reached late-stage clinical development in more than a decade. Nabriva has announced positive topline data for lefamulin from the first of its two global, registrational Phase 3 clinical trials evaluating lefamulin in patients with moderate to severe community-acquired bacterial pneumonia (CABP).

Number of Employees: 73

 
 • Price / Volume Information   
Yesterday's Closing Price: $0.19 Daily Weekly Monthly
20 Day Moving Average: 643,634 shares
Shares Outstanding: 632.05 (millions)
Market Capitalization: $122.11 (millions)
Beta: 1.57
52 Week High: $1.57
52 Week Low: $0.19
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -41.46% -35.90%
12 Week -58.63% -53.51%
Year To Date -67.74% -60.59%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
25-28 NORTH WALL QUAY IFSC
-
DUBLIN,L2 19406
IRL
ph: 353-1649-2000
fax: 610-816-6639
david.garrett@nabriva.com http://www.nabriva.com
 
 • General Corporate Information   
Officers
Theodore Schroeder - Chief Executive Officer and Director
Daniel Burgess - Chairman
Daniel Dolan - Chief Financial Officer
Steven Gelone - President; Chief Operating Officer and Director
Colin Broom - Director

Peer Information
Nabriva Therapeutics AG (CORR.)
Nabriva Therapeutics AG (RSPI)
Nabriva Therapeutics AG (CGXP)
Nabriva Therapeutics AG (BGEN)
Nabriva Therapeutics AG (GTBP)
Nabriva Therapeutics AG (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: G63637113
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/04/22
Share - Related Items
Shares Outstanding: 632.05
Most Recent Split Date: 12.00 (0.10:1)
Beta: 1.57
Market Capitalization: $122.11 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.19 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.73 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/04/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 2.67
Price/Cash Flow: -
Price / Sales: 3.55
EPS Growth
vs. Year Ago Period: 62.26%
vs. Previous Quarter: 16.67%
Sales Growth
vs. Year Ago Period: 217.12%
vs. Previous Quarter: -13.40%
ROE
03/31/22 - -82.07
12/31/21 - -82.13
09/30/21 - -98.31
ROA
03/31/22 - -57.11
12/31/21 - -57.36
09/30/21 - -67.28
Current Ratio
03/31/22 - 4.01
12/31/21 - 3.59
09/30/21 - 4.48
Quick Ratio
03/31/22 - 3.05
12/31/21 - 2.94
09/30/21 - 3.69
Operating Margin
03/31/22 - -137.52
12/31/21 - -171.14
09/30/21 - -245.41
Net Margin
03/31/22 - -137.52
12/31/21 - -171.14
09/30/21 - -245.41
Pre-Tax Margin
03/31/22 - -135.62
12/31/21 - -169.44
09/30/21 - -243.21
Book Value
03/31/22 - 0.07
12/31/21 - 0.09
09/30/21 - 0.12
Inventory Turnover
03/31/22 - 1.18
12/31/21 - 1.07
09/30/21 - 0.81
Debt-to-Equity
03/31/22 - 0.09
12/31/21 - 0.08
09/30/21 - 0.08
Debt-to-Capital
03/31/22 - 8.07
12/31/21 - 7.40
09/30/21 - 7.55
 

Powered by Zacks Investment Research ©